Media headlines about KemPharm (NASDAQ:KMPH) have trended somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. KemPharm earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.7742156973071 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of KemPharm (KMPH) traded up $0.05 during mid-day trading on Tuesday, reaching $3.80. The company had a trading volume of 7,000 shares, compared to its average volume of 43,173. KemPharm has a 1-year low of $2.45 and a 1-year high of $5.40. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of -1.92.
Several research analysts have recently issued reports on the company. Canaccord Genuity set a $7.00 price objective on KemPharm and gave the company a “buy” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. set a $13.00 price objective on KemPharm and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $9.00.
WARNING: This piece of content was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/15/kempharm-kmph-receiving-somewhat-favorable-media-coverage-report-finds.html.
In other KemPharm news, major shareholder Delaware Street Capital Master purchased 325,888 shares of the business’s stock in a transaction on Thursday, September 14th. The shares were purchased at an average cost of $3.27 per share, for a total transaction of $1,065,653.76. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have acquired a total of 335,188 shares of company stock worth $1,090,088 over the last 90 days. Company insiders own 25.40% of the company’s stock.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.